Catalyst overview
Research summary
This catalyst tracks a Approved update for Iberdomide + (daratumumab + dexamethasone) in Multiple Myeloma. The expected timing is based on the latest available company guidance and may change.
EXCALIBER-RRMM study. 9/23/25- Interim analysis reported. Trial ongoing, evaluating dual-primary endpoint of PFS & key secondary endpoints. 02/17/26:- FDA accepted NDA for IberDd in relapsed or refractory multiple myeloma; Breakthrough and Priority Review granted; PDUFA August 17, 2026. 08/11/26:- FDA approved ZENBEXUS (IberDd) for relapsed or refractory multiple myeloma.
Verification
Confirm timing and program details against the company announcement or filing.